Back to Browse Journals » International Journal of Chronic Obstructive Pulmonary Disease » Volume 3 » Issue 4

Long-acting β2-agonists (LABA) in chronic obstructive pulmonary disease: efficacy and safety

Authors Andrea Rossi, Sonia Khirani, Mario Cazzola

Published 5 December 2008 Volume 2008:3(4) Pages 521—529


Andrea Rossi1, Sonia Khirani1, Mario Cazzola2

1Unit of Respiratory Diseases, Hospital of Bergamo, Bergamo, Italy; 2Unit of Respiratory Diseases, Department of Internal Medicine, University of Rome ‘Tor Vergata’, Rome, Italy

Abstract: COPD is characterized by progressive airflow obstruction which does not fully reverse to inhaled or oral pharmacotherapy. The management of patients with COPD has taken a totally new direction over the past 20 years, thank to the use of novel therapies aimed to improve and modify the natural history of COPD. Long-acting bronchodilators, including long-acting β2-agonists (LABAs), were introduced several years ago in order to enhance improvements in lung function, health status related quality of life, and reduce the rate of exacerbations. These effects can be boosted by the combination of LABAs with long-acting anticholinergic, and/or with inhaled corticosteroids. Inhaled LABAs are commonly well tolerated although adverse effects such as tremor and palpitations are occasionally troublesome.

Keywords: LABA, COPD, efficacy, safety

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at:

Readers of this article also read:

Characterization of renal biomarkers for use in clinical trials: effect of preanalytical processing and qualification using samples from subjects with diabetes

Brott DA, Furlong ST, Adler SH, Hainer JW, Arani RB, Pinches M, Rossing P, Chaturvedi N

Drug Design, Development and Therapy 2015, 9:3191-3198

Published Date: 22 June 2015

Applications of calixarenes in cancer chemotherapy: facts and perspectives

Yousaf A, Abd Hamid S, Bunnori NM, Ishola AA

Drug Design, Development and Therapy 2015, 9:2831-2838

Published Date: 2 June 2015

Clinical variables impacting on the estimation of utilities in chronic obstructive pulmonary disease

Miravitlles M, Huerta A, Valle M, García-Sidro P, Forné C, Crespo C, López-Campos JL

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:367-377

Published Date: 16 February 2015

An evidence-based update on the pharmacological activities and possible molecular targets of Lycium barbarum polysaccharides

Cheng J, Zhou ZW, Sheng HP, He LJ, Fan XW, He ZX, Sun T, Zhang X, Zhao RJ, Gu L, Cao CH, Zhou SF

Drug Design, Development and Therapy 2015, 9:33-78

Published Date: 17 December 2014

Histological type-specific prognostic factors of cervical small cell neuroendocrine carcinoma, adenocarcinoma, and squamous cell carcinoma

Intaraphet S, Kasatpibal N, Søgaard M, Khunamornpong S, Patumanond J, Chandacham A, Chitapanarux I, Siriaunkgul S

OncoTargets and Therapy 2014, 7:1205-1214

Published Date: 1 July 2014

The Nanomaterial Registry: facilitating the sharing and analysis of data in the diverse nanomaterial community

Ostraat ML, Mills KC, Guzan KA, Murry D

International Journal of Nanomedicine 2013, 8:7-13

Published Date: 16 September 2013

Identifying targets for COPD treatment through gene expression analyses

Zhi-Hua Chen, Hong Pyo Kim, Stefan W Ryter, Augustine MK Choi

International Journal of Chronic Obstructive Pulmonary Disease 2008, 3:359-370

Published Date: 12 September 2008